Published Date: 01-02-2019
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global Smart Insulin Pen Market, published by KBV research, The Global Smart Insulin Pen Market size is expected to reach $117.3 million by 2024, rising at a market growth of 10.2% CAGR during the forecast period.
The North America market would dominate the Global Second Generation Pens Market by Region in by 2024, growing at a CAGR of 9.7 % during the forecast period. The Europe market is expected to witness a CAGR of 10.2% during (2018 - 2024). Additionally, The Asia Pacific market is expected to witness a CAGR of 11.9% during (2018 - 2024).
The Hospitals & Clinics market dominated the Global Smart Insulin Pen Market by End User in 2017. The Ambulatory Surgical Centers market is expected to witness a CAGR of 10.6% during (2018 - 2024).
The Prefilled market dominated the Global Smart Insulin Pen Market by Usability in 2017, and would achieve a market value of $64,759.4 Thousand by 2024. The Reusable market is expected to witness a CAGR of 10.7% during (2018 - 2024).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Companion Medical Inc., Digital Medics Ptd Ltd., Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co., Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Emperra GmbH E-Health Technologies, Jiangsu Delfu medical device Co. Ltd., Bigfoot biomedica.
By End User
Unique Offerings from KBV Research